Role of Caspase-3, Phosphatidylinositol-3 Kinase (PI3K), and 3-methylhistidine (3-MH) in the Pathophysiology of Skeletal Muscle Loss in Weight-losing Pancreas Cancer Patients
- Compare levels of caspase-3 and phosphorylated Akt (pAkt) in the rectus abdominous
muscle of patients with pancreatic cancer who are experiencing cachexia and are
undergoing surgery for diagnosis or primary therapy with patients who have not lost
weight and are undergoing abdominal surgery for nonmalignant conditions.
- Compare levels of urinary 3-methylhistidine (3-MH) in these patients.
- Evaluate possible correlations of caspase-3 activity, pAkt, and urinary 3-MH with early
time to progression and subsequent lean body weight loss in patients with pancreatic
- Associate excretion of urinary 3-MH with higher levels of caspase-3 activity and pAkt
to analyze the utility of 3-MH as a marker of skeletal muscle proteolysis.
OUTLINE: This is a pilot study.
During surgery, a muscle biopsy is performed and approximately 1 cm of rectus abdominous
muscle is obtained for analysis. Caspase-3 activity and total/phosphorylated
phosphatidylinositol-3 kinase and Akt are measured in muscle biopsies by western blot
analysis. 3-methylhistidine activity is measured in urine samples.
After completion of study, patients with pancreatic cancer are followed postoperatively at 3
and 6 months.
PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Skeletal muscle loss
Joanna M. Brell, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
United States: Federal Government
|Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|